BladderBLOG: Gender-related Characteristics of Bladder Cancer Treatment

Sponsor
University of Florence (Other)
Overall Status
Recruiting
CT.gov ID
NCT04687254
Collaborator
marco Carini (Other), Sergio Serni (Other), Andrea Minervini (Other), Pietro Spatafora (Other), Giandomenico Roviello (Other), Gabriella Nesi (Other), Ilaria Camilla Galli (Other), Calogero Saieva (Other), Graziano Vignolini (Other), Giovani Tasso (Other), Simone Morselli (Other)
500
1
9
55.7

Study Details

Study Description

Brief Summary

The most frequent cancer of the urinary tract is the bladder cancer (BC), in Italy its incidence reaches the 7% of all the new diagnosis of cancer, accounting for the fifth cause of death in the western countries, overall 140.000 new cases per year in Europe. In the year 2017, the Italian association for medical oncology (AIOM) recorded in our country about 21.700 new diagnosis of BC men and 5.300 in women. This data show not only a relevant gender disparity on the disease incidence (in 5th to 7th decade male incidence: 11-12% of all new diagnosis of cancer versus 1% in women) but also on the outcomes of treatment. Overall, the 30% of all the new diagnosis have a muscle-invasive (MIBC) onset, the female gender suffer a correlation with a more advanced disease at the time of first diagnosis. As a consequence, men have lower BC-related mortality when compared to women (p<0,001). This discrepancy in the mortality rate has been investigated by many authors, resulting in the evidence that female gender suffers higher risks, especially during the first two-years after the radical cystectomy. A comprehensive explanation has not been formulated yet, but a multiplicity of cofactors, including variations in the hormone receptors and tumor biology as well as the different anatomy between male and female, have been identified as potentially relevant. Another important issue in the pre-operatory management of female patients with BC is the misleading interpretation of hematuria. It seems to directly correlate with the evidence that women suffer a more advanced stage at diagnosis, and this element has been withheld in the list of relevant risk factors for prognosis. Nevertheless, a thorough analysis of their effect will only be possible in the future, as well-designed prospective and randomized clinical trials are currently not available.

A part from the preoperatory disparity, it has also been described that men are more frequently candidates to an orthotopic urinary diversion, leading female patients to an irreversibly altered perception of personal integrity and body image, namely to a lower quality of life after radical cystectomy. The female anatomy has been considered as a limitation to continence recovery, resulting in preoperative counselling more frequently against in favor of ileal conduit or not-continent urinary diversions.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Gender-related Characteristics of Bladder Cancer Treatment. Therapeutic Offer, Pathologic Features and Survival Outcomes of Patients Treated With Radical Cystectomy for Muscle-invasive Bladder Cancer
    Actual Study Start Date :
    Sep 1, 2020
    Anticipated Primary Completion Date :
    Apr 1, 2021
    Anticipated Study Completion Date :
    Jun 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. gender-related discrepancies in the treatment offer for patients affected by MIBC from September 2016 to December 2020 [36 months]

    Secondary Outcome Measures

    1. gender-related difference in the clinical and pathologic features of MIBC [36 months]

    2. gender-related difference in the survival outcomes [36 months]

    3. gender-related difference in the risk factors for development of BC [36 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient undergoing radical cystectomy since September 2016 December 2020

    • Development of bladder cancer confirmed histologically

    • Written informed consent

    Exclusion Criteria:

    • Lack of clinical and prognostic data on selected patients

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Donata Villari Firenze FI Italy 50100

    Sponsors and Collaborators

    • University of Florence
    • marco Carini
    • Sergio Serni
    • Andrea Minervini
    • Pietro Spatafora
    • Giandomenico Roviello
    • Gabriella Nesi
    • Ilaria Camilla Galli
    • Calogero Saieva
    • Graziano Vignolini
    • Giovani Tasso
    • Simone Morselli

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Donata Villari, Researcher, University of Florence
    ClinicalTrials.gov Identifier:
    NCT04687254
    Other Study ID Numbers:
    • 18094/OSS
    First Posted:
    Dec 29, 2020
    Last Update Posted:
    Dec 29, 2020
    Last Verified:
    Dec 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 29, 2020